Seshadri Neervannan insider trades: Tarsus Pharmaceuticals (TARS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Seshadri reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 20, 2026 | TARS | ↓ Sell | 2,989 | $66.75 | $200K | Direct | Mar 24, 2026 (4d) |
| Mar 4, 2026 | TARS | ↓ Sell | 8,366 | $76.67 | $641K | Direct | Mar 5, 2026 (1d) |
| Mar 20, 2025 | TARS | ↓ Sell | 7,583 | $47.89 | $363K | Direct | Mar 20, 2025 (0d) |
| Mar 18, 2024 | TARS | ↓ Sell | 4,879 | $30.60 | $149K | Direct | Mar 19, 2024 (1d) |
| Mar 23, 2023 | TARS | ↓ Sell | 1,141 | $12.55 | $14K | Direct | Mar 23, 2023 (0d) |
| Mar 20, 2023 | TARS | ↓ Sell | 740 | $12.94 | $10K | Direct | Mar 21, 2023 (1d) |
| Mar 16, 2023 | TARS | ↓ Sell | 357 | $13.43 | $5K | Direct | Mar 17, 2023 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TARS insiders
Open-market trades in the last 12 months
About Seshadri Neervannan's insider trades
Seshadri Neervannan is Chief Operating Officer at Tarsus Pharmaceuticals (TARS). Since Mar 16, 2023, Seshadri has reported no open-market purchases and 7 sales worth $1.4M on SEC Form 4. In the last 12 months: 2 sales ($841K).
Their filings also include grants and awards (6 filings), option exercises (4 filings), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TARS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.